Actively Recruiting

Early Phase 1
Age: 18Years +
MALE
ID05045066

Differences in Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients With Localized Versus Metastatic Disease

Led by Mayo Clinic · Updated on 2026-06-08

220

Participants Needed

2

Research Sites

156 weeks

Total Duration

On this page

Sponsors

M

Mayo Clinic

Lead Sponsor

C

Congressionally Directed Medical Research Programs

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying vitamin D insufficiency in African American men who have had prostate cancer, whether it is localized, locally recurrent, or metastatic. The study aims to understand how low vitamin D levels affect the immune system and whether replacing vitamin D can normalize immune function. This early phase I trial also explores differences in immune cell function between patients at different stages of prostate cancer and compares immune responses with those of West African patients from Nigeria. Participants with low vitamin D levels will take cholecalciferol (a form of vitamin D) by mouth daily for 8 weeks, as long as no unacceptable side effects occur. Blood samples will be collected throughout the treatment period to monitor immune cell function. After treatment, patients will be followed up at 56 days and then annually for up to 3 years to observe longer-term effects, including prostate-specific antigen progression free survival. During the study, participants will undergo blood tests and quality-of-life assessments. Researchers will measure changes in immune cell function from the start of the study to 8 weeks after treatment begins. They will also track vitamin D insufficiency prevalence and the possible link between vitamin D replacement and prostate cancer progression over several years. The study will monitor safety and immune response changes throughout the follow-up period.

CONDITIONS

Brief Title

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • African American males aged 18 years or older
  • History of localized, metastatic, or locally recurrent prostate cancer
  • Vitamin D levels below 30 ng/ml
Not Eligible

You will not qualify if you...

  • Known allergy to vitamin D
  • End stage renal failure requiring dialysis
  • Liver cirrhosis
  • Taking vitamin D or multivitamin supplements with more than 400 IU of vitamin D daily in the past month
  • Medical or psychological conditions preventing study completion or informed consent
  • Chemotherapy, surgery, or radiation treatment within 3 weeks before blood collection
  • History of high blood calcium levels (hypercalcemia)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 8 weeks

Participants with low vitamin D3 levels receive cholecalciferol orally daily for 8 weeks in the absence of unacceptable toxicity. Blood samples are collected throughout this period to monitor immunological cell function and vitamin D levels.

Multiple visits for blood sample collection during treatment

Follow-up

Duration - Up to 3 years

After completing vitamin D treatment, participants are followed up at 56 days and then annually for 3 years to monitor PSA progression free survival and immune response.

1 visit at 56 days post-treatment and annual visits for 3 years

Trial Site Locations

Total: 2 locations

1

Mayo Clinic in Arizona

Scottsdale, Arizona, United States, 85259

Actively Recruiting

2

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224-9980

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials Referral Office

C

Cancer Center Clinical Trials

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

24 Gy in One Fraction Urethral-sparing High-Dose-Rate Like S...

Localized Prostate Carcinoma

Actively Recruiting

1 location

Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to In...

Castration-Resistant Prostate Carcinoma

Actively Recruiting

1 location

A Pragmatic Phase II Study Evaluating Tolerability in Prosta...

Advanced Prostate Adenocarcinoma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here